Given the inherent expertise of CMOs and CDMOs, they are believed to be capable of enabling reduction in product development timelines, significant cost-benefits, as well as provide drug developers access to larger production capacities and novel technologies
Roots Analysis has announced the addition of “Pharmaceutical Contract Manufacturing Market (3rd Edition), 2021-2030” report to its list of offerings.
The incremental evolution in product discovery, clinical investigation and manufacturing methods have rendered outsourcing a crucial aspect of pharmaceutical development and production. Considering the various advantages associated with outsourcing certain operations, we are led to believe that the pharmaceutical contract manufacturing market is likely to witness positive growth in the coming years.
To order this 510 page report, which features 180+ figures and 175+ tables, please visit